Studies whether the migraine drug galcanezumab passes into breastmilk
Studies galcanezumab in breastmilk of women with migraine who are nursing.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Emgality for Migraine in Breastmilk
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 26 Feb 2024
- Expected to end
- Apr 2028
- Type of study
- Observational
- Treatments tested
- Galcanezumab
- Record updated
- 11 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-45 with migraine who are still breastfeeding and plan to take galcanezumab after giving birth. It studies how much of the drug reaches breastmilk.
- Age
- 18 to 45 years
- Sex
- Women only
- Disease stage
- Established diagnosis of migraine. Between 14 days and 9 months after birth, still nursing, after an uncomplicated delivery.
- Earlier treatment
- Planning to receive galcanezumab after the birth. Cannot have used gepants.
Main reasons for not taking part
- Use of gepants
- Moderately severe or severe depression (PHQ9 score 15 or above)
- Pregnant or planning pregnancy in the next 6 months
- Severe mastitis
- Infant with severe medical issues, or a NICU stay longer than 3 nights
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Female
- Childbearing age (18-45)
- Established diagnosis of migraine
- Status post uncomplicated delivery (no long-term maternal complications)
- No prolonged (>3 night) NICU stay for infant
- Between 14 days and 9 months postpartum, and still nursing, at the time of enrollment
- Planning to receive galcanezumab postpartum
- Suitable candidate to receive galcanezumab postpartum, at discretion of prescribing clinician
Who cannot take part
- Contraindications to breastfeeding, such as prior surgery or infant contraindications
- Patients of infants with severe medical issues identified in the health record (developmental issues, delivery issues, concomitant medications)
- Contraindications to galcanezumab or insurance coverage
- Use of gepants
- Moderately Severe or Severe Depression as established by the PHQ9 screen (i.e. score 15 or above)
- Pregnant or planning pregnancy in the coming 6M
- Patients with severe mastitis will not be enrolled; should mastitis occur during the study, this will be included as a covariate and results analyzed accordingly
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Where in United States
- University of California San FranciscoSan Francisco, United StatesContact: Ayushi D Balan, BA, BSTaking people
About the trial
What the trial wants to find out
The goal of this project is to evaluate galcanezumab transfer into maternal breastmilk, and to evaluate infant (growth, development, constipation, colic, infections) and maternal (headache) outcomes for dyads in which the mother was treated with galcanezumab and to compare outcomes for infants who were or were not breastfed after maternal treatment.
Read full original descriptionShow less
In this prospective observational study, the study team proposes to prospectively collect serial milk samples from 30 adult women who are treated with galcanezumab for migraine. Mothers who are interested in participating will be connected with us, the main clinical site, by neurologists across the USA. Mothers must carry a diagnosis of migraine, be aged 18-45 years, and be between 14 days and 9 months postpartum, and still nursing, at the time of enrollment.
This study will fill a significant unmet need as women of childbearing potential are over-represented in the migraine population, and yet they are excluded from clinical trials of migraine treatments during pregnancy and lactation.
The group in the trial
- Galcanezumab
Postpartum women both nursing and receiving treatment for migraine with galcanezumab.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Evaluation of Emgality (Galcanezumab) in Breastmilk in Adult Women With Migraine
- Plain-language title
- Studies whether the migraine drug galcanezumab passes into breastmilkGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06085144, who can take part
- Record updated
- 11 August 2026